AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis from its first-in-human proof-of-concept study (“PoC 1”) and recent progress made towards the start of U.S. clinical trials, on track to begin in 2026.

The CEO Corner segment is now available .

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.



For more information, visit and connect with the Company on , , and .

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
02/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. Featured in Two Innovation in Interventional C...

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the (TCT 2025) being held October 25-28, 2025 in San Francisco, CA. The presentations will highlight positive results from the initial phase of Autonomix...

 PRESS RELEASE

Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Abla...

Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will participate at the , taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. As part of the conference, mem...

 PRESS RELEASE

Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Ena...

Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology  With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company d...

 PRESS RELEASE

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segme...

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment THE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis from its first-in-human proof-of-concept study (“PoC 1”) and recent progress made towards the start of U.S. clinical trials, on trac...

 PRESS RELEASE

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study...

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System  GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a Good L...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch